US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Brewers starter Joe Ross leaves after first inning vs. Marlins with lower back strain
MIAMI (AP) — Milwaukee Brewers right-hander Joe Ross left his start against the Miami Marlins on Mon2024-05-21Peng urges German chorus to use music as bridge
Peng Liyuan, wife of President Xi Jinping, interacts with the visiting members of Burg Chinese Choru2024-05-21- China and the Netherlands highlighted their shared commitment to opposing the severing of industrial2024-05-21
Catastrophic famine looms in Gaza
Aid agencies call for truce as hunger warnings mountMultiple international humanitarian agencies hav2024-05-21With Djokovic awaiting the winner, Murray trails Hanfmann at rain
GENEVA (AP) — Needing a win to face Novak Djokovic next at the Geneva Open, Andy Murray was saved by2024-05-21Xi calls for steps to energize central region
President Xi Jinping called on Wednesday for concrete steps to propel the rise of China's central re2024-05-21
atest comment